AZ, HutchMed’s savolitinib gets 1st approval in China for NSCLCAstraZeneca and HutchMed have claimed their first approval – in China – for cMET inhibitor savolitinib as a Share XAZ, HutchMed’s savolitinib gets 1st approval in China for NSCLChttps://pharmaphorum.com/news/az-hutchmeds-savolitinib-gets-1st-approval-in-china-for-nsclc/
